STOCK TITAN

Anavex Life Sciences Corporation - AVXL STOCK NEWS

Welcome to our dedicated news page for Anavex Life Sciences Corporation (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Sciences Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anavex Life Sciences Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anavex Life Sciences Corporation's position in the market.

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) will present at the 23rd Annual Needham Virtual Healthcare Conference, showcasing their therapeutics for neurodegenerative disorders. Christopher U Missling, PhD, President & CEO, will present on April 8, 2024, with a live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
conferences
-
Rhea-AI Summary
Anavex Life Sciences Corp. announces the screening of the first patient in the Phase 2 clinical study of ANAVEX®3-71 for schizophrenia treatment. The trial aims to investigate positive, negative, and cognitive symptoms of schizophrenia using a novel mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
clinical trial
-
Rhea-AI Summary
Anavex Life Sciences Corp. announces participation in the 44th Annual TD Cowen Health Care Conference. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company's developments in neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease and Parkinson's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
Rhea-AI Summary
Anavex Life Sciences Corp. reported financial results for its fiscal quarter ended December 31, 2023, and provided updates on its key pipeline including blarcamesine for Alzheimer's disease and other CNS diseases. The company also announced various business highlights and financial data, including cash and cash equivalents of $143.8 million at December 31, 2023, and a net loss of $8.6 million for the first quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
earnings
-
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) will release its financial results for the fiscal quarter ended December 31, 2023, on February 7, 2024. The company will host a conference call to review the financial results and provide an update on its growth strategy. Anavex is a clinical-stage biopharmaceutical company focusing on therapeutics for neurodegenerative and neurodevelopmental disorders. The webcast and conference call information are available on Anavex's website and can be accessed by dialing a phone number for participants in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
earnings
-
Rhea-AI Summary
Anavex Life Sciences Corp. announced the findings from the ANAVEX®3-71 first-in-human study, which achieved its safety objectives. The study demonstrated that ANAVEX®3-71 is linear, dose proportional, and time invariant at single ascending doses of 5 to 200 mg, with no effect from food. The publication further supports ANAVEX®3-71's drug development program, showcasing its potential to treat cognitive and behavioral deficits in neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
Rhea-AI Summary
Anavex Life Sciences Corp. announces the initiation of a placebo-controlled Phase 2 trial of ANAVEX®3-71 for the treatment of schizophrenia, which is expected to begin in Q2 2024. ANAVEX®3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects, offering the potential to treat all symptom domains of schizophrenia without the side effects of standard antipsychotics. The trial will study positive, negative, and cognitive domains of schizophrenia based on ANAVEX®3-71’s ability to synergistically activate both SIGMAR1 and M1 muscarinic receptors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
clinical trial
-
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) has been granted a new U.S. Patent expanding the coverage of ANAVEX®2-73 (blarcamesine) therapy to address a range of symptoms exhibited by patients suffering from neurodevelopmental and neurological conditions related to MeCP2 gene mutations. The patent is expected to remain in force until at least January 2037, further reinforcing the company's position in providing novel and effective therapies for debilitating neurodevelopmental and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
none
-
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announces participation in the 42nd Annual J.P. Morgan Healthcare Conference. President and CEO, Christopher U Missling, PhD, to present on January 11, 2024, at 10:30am PST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
conferences
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced topline results from the Phase 2/3 EXCELLENCE clinical study in pediatric Rett Syndrome. The study evaluated the clinical efficacy, safety, and tolerability of 30 mg ANAVEX®2-73 in 92 pediatric patients. The study showed improvement in the Rett Syndrome Behaviour Questionnaire (RSBQ) but did not meet the Clinical Global Impression – Improvement scale (CGI-I). Anavex believes a high placebo response may have masked the therapeutic effect of the drug. A preliminary review of the safety results indicates no new safety signals in the study. Over 91% of patients completing the trial continued into a 48-week open-label extension study (OLE), which is ongoing. The company has established Compassionate Use Programs in Canada, Australia, and the UK for pediatric patients. ANAVEX®2-73 has previously received Fast Track designation, Rare Pediatric Disease designation, and Orphan Drug designation from the FDA for the treatment of Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.07%
Tags
none
Anavex Life Sciences Corporation

Nasdaq:AVXL

AVXL Rankings

AVXL Stock Data

415.49M
79.52M
3.14%
32.07%
24.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AVXL

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.